Skip to content

DSUR (Development Safety Update Report)

Last reviewed

A Development Safety Update Report (DSUR) is the annual safety report for a drug in clinical development. It presents the safety information from all clinical trials of the investigational product that were ongoing or completed during the reporting period, and is submitted to the health authorities overseeing those trials.

Key facts

GuidelineICH E2F
Applies toInvestigational drugs and biologics, from the first clinical trial authorisation until development ends
FrequencyOnce a year
Reporting period startsThe Development International Birth Date (DIBD), the date of the first trial authorisation in any country
DueNo later than 60 calendar days after the data lock point
Post-approval counterpartPBRER (called PSUR in the EU)

What a DSUR contains

The report summarises the status of the clinical programme, estimated cumulative exposure, interval line listings of serious adverse reactions, cumulative summary tabulations of serious adverse events, significant findings from trials and other sources, and an overall safety assessment with a summary of important risks.

Sources

Read more